Sánchez-Mendiola M, Martínez-Natera OC, Herrera-Maldonado N, Ortega-Arroyo J

Language: Spanish
References: 12
Page: 267-272
PDF size: 72.08 Kb.

ABSTRACT

Background: Hyaline membrane disease (HMD) due to lung surfactant deficiency in the preterm newborn is an important cause of neonatal morbidity and mortality. Exogenous lung surfactant has transformed HMD therapy in developed countries, but an equivalent benefit has not been accomplished in developing countries due to a variety of factors. Porcine surfactant developed in Cuba is an inexpensive alternative to other surfactants, and its use has not been studied in our settings.
Methods: A randomized, open, prospective and controlled trial was undertaken in 44 preterm newborns with HMD diagnosis. One group received bovine surfactant (BS) (Survanta) and the other Cuban porcine surfactant (PS) (Surfacen). The following clinical response variables were evaluated: oxygenation and ventilation indexes, days with supplementary oxygen, days with mechanical ventilation, incidence of complications, time of hospitalization, and mortality.
Results: 23 Patients received bovine surfactant and 21 the porcine type. The two groups were clinically similar, with patterns of oxygenation and ventilation response that were the same between groups, with a tendency to higher initial oxygenation increase in the PS group. The incidence of complications was similar between groups. Ten Patients (47.6%) died in the PS group, versus 12 (52.2%) in the BS group (p›0.05).
Conclusions: Porcine surfactant had similar clinical effects than bovine surfactant in the oxygenation and ventilation variables, with no significant differences in complications or mortality. Porcine surfactant is an effective and lower cost alternative to bovine surfactant in the treatment of HMD.

REFERENCES

1. 1. Fujiwara T, Maeta H, Chida S et al. Artificial surfactant therapy in hyaline membrane disease. Lancet 1980;1:55-59.

2. 2. Jobe AH, Ikegarni M. Surfactant for the treatment of respiratory distress syndrome. Am Rev Resp Dis 1987;136:1256-1275.

3. 3. Arizmendi-Dorantes JG, Camarero-Benítez CC. Síndrome de insuficiencia respiratoria neonatal. Experiencia de cinco años en el Hospital Central Militar de México (1980-1984). Rev Sanid Milit Méx 1987;41:151-155.

4. 4. Jobe AH. Pulmonary surfactant therapy. N Engl J Med 1993;328:861-868.

5. 5. Soll RF. Natural surfactant extract vs. synthetic surfactant in the treatment of established respiratory distress syndrome (Cochrane Review). En: The Cochrane Library, Issue 3, 2003.Oxford. Update Software.

6. 6. Speer CP, Gefeller O, Groneck P et al. Randomized clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed 1995;72:F8-13.

7. 7. Long WA, Zeng G, Henry GW. Pharmacologic adjuncts II: Exogenous surfactants. En: Assisted Ventilation of the Neonate. Goldsmith JP, Karotkin EH (Eds.) VM Saunders Co. 3a. Edition Philadelphia, 1996. p. 305-325.

8. 8. Rosello JD, Hayward PE, Martell M et al. Hyaline membrane disease (HMD) therapy in Latin America: impact of exogenous surfactant administration on newborn survival, morbidity and use of resources. J Perinat Med 1997;25:280-287.

9. 9. López-Candiani C, Valencia-Salazar G, Rodríguez-Weber M. Enfermedad por membranas hialinas. Epidemiología en el Instituto Nacional de Pediatría. Acta Ped Mex 1994;15:169-174.

10. Clements JA, Avery ME. Lung surfactant and neonatal respiratory distress syndrome. Am J Respir Crit Care Med 1998;157:S59-S66.

11. Kattwinkel J. Surfactant: evolving issues. Clin Perinatol 1998;25:17-32.

12. Dekowski SA, Holtzman RB. Surfactant replacement therapy. Pediatr Clin North Am 1998;45:549-571.